Marie-Paule Kieny

BIOQUAL Announces COVID-19 Vaccine Testing

Retrieved on: 
Tuesday, March 31, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Other Health, Medical specialties, Medicine, Infectious diseases, Virology, RTT, Vaccination, Vaccine, Chikungunya, Nelson Michael, Marie-Paule Kieny

BIOQUAL announces the development of programs for in-vivo testing of COVID-19 candidate vaccines.

Key Points: 
  • BIOQUAL announces the development of programs for in-vivo testing of COVID-19 candidate vaccines.
  • For a number of years, BIOQUAL has been engaged in development of in-vivo testing programs and has been extensively involved in research efforts to develop vaccine and therapies against emerging diseases including AIDS, Hepatitis, Zika, Chikungunya and many others.
  • The company is now focused on COVID-19 research and is positioned to play an important role in the development of successful vaccines and therapies against this epidemic.
  • Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties.